Regulus Therapeutics' (RGLS) Abstract on RG-101 Not Presented at AASLD Conference

November 14, 2016 4:46 PM EST

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

Regulus Therapeutics (NASDAQ: RGLS) said to withdraw abstract n RG-101, which was slated for presentation at AASLD last Saturday, according to Bloomberg.

Regulus' IND for RG-101 was placed on clinical hold in June.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

FDA, Trader Talk

Add Your Comment